Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAP2 | P11137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6254129 | 0.91 | DHODH (0.49) | KDM4EALDH1A1HPGDDHODHMEN1 | |
| SCHEMBL6259344 | 0.89 | ESR1 (0.44) | DHODHMAPT | |
| SCHEMBL6254155 | 0.88 | KDM4E (0.49) | KDM4EALDH1A1HPGDFOLH1MEN1 | |
| SCHEMBL6252604 | 0.86 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGDFOLH1MEN1 | |
| SCHEMBL6256491 | 0.84 | DHODH (0.44) | KDM4EALDH1A1HPGDDHODHMEN1 | |
| SCHEMBL7239550 | 0.83 | DHODH (0.42) | KDM4EALDH1A1HPGDDHODHMEN1 | |
| SCHEMBL6252383 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1HPGDFOLH1MEN1 | |
| SCHEMBL6255915 | 0.82 | DHODH (0.43) | KDM4EDHODH | |
| SCHEMBL6254125 | 0.80 | APEX1 (0.41) | KDM4EALDH1A1HPGDDHODHMEN1 | |
| SCHEMBL6252220 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1HPGDFOLH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156116-A1 | Bis-indolyquinone compounds | TANG PENG CHO (US) | 2002-10-24 | — | — | US | claimed |
| EP-1218342-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | Sugen, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| US-6376529-B1 | INSULIN DISEASES; ANTIDIABETIC AGENTS | SUGEN, INC. | 2002-04-23 | — | — | US | claimed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | claimed |
| US-6660763-B2 | Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy | SUGEN, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20020156116-A1 | Bis-indolyquinone compounds | TANG PENG CHO (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1218342-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | Sugen, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6376529-B1 | INSULIN DISEASES; ANTIDIABETIC AGENTS | SUGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156116-A1 | Bis-indolyquinone compounds | IRS1, GRK2, GID4 | KDM4E 3407/4885ALDH1A1 4519/4885HPGD 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.